Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : AZN save search
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Published: 2024-02-08 (Crawled : 12:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -8.5%
H: 2.46%
C: 2.46%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.68%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -6.81%
H: 3.02%
C: 2.42%
fda granted designation eplontersen
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.155 -8.28% -9.03% 670K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 2.56%
C: 2.56%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.63%
H: 4.97%
C: 2.76%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: 0.47%
H: 1.7%
C: -0.38%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.59%
H: 0.62%
C: -0.56%
fda year review cancer pancreatic
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.7%
H: 0.86%
C: 0.58%
fda fda approval research approval lupus
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Published: 2021-06-07 (Crawled : 19:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.32%
H: 0.6%
C: -0.39%
fda fda approval children approval
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
Published: 2021-05-10 (Crawled : 16:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.63%
H: 0.95%
C: -2.15%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.38%
H: 0.27%
C: -0.31%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.7%
H: 1.1%
C: -1.32%
fda license application
US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight to 2026: Insight on FDA Approved 57 Cancer Antibodies Available in the US Market
Published: 2021-04-09 (Crawled : 13:37) - prnewswire.com
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.31%
H: 0.02%
C: -0.42%
sales fda clinical trials cancer antibody drug trial fda approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.